WallStreetZenWallStreetZen

NYSE: ABBV
Abbvie Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Abbvie earnings were $4.2B for the trailing 12 months ending Mar 31, 2025, with -30% growth year over year. The latest ABBV earnings report on Mar 31, 2025 announced Q1 2025 earnings of $1.3B, down 5,945.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ABBV reported annual earnings of $4.3B, with -12% growth. The next ABBV earnings date is Jul 23, 2025.

ABBV past earnings growth

How has ABBV's earnings growth performed historically?

Company
-29.97%
Industry
114.16%
Market
34.26%
ABBV's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ABBV's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ABBV's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ABBV earnings history

Current Revenue
$57.4B
Current Earnings
$4.2B
Current Profit Margin
7.3%
ABBV's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

ABBV Return on Equity

Current Company
95.6%
Current Industry
53.5%
Current Market
31.3%
ABBV's Return on Equity (95.6%)... subscribe to Premium to read more.
High Return on Equity Performance

ABBV undefined

Current Company
3%
Current Industry
10.1%
ABBV is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ABBV announces earnings.

ABBV undefined

Current Company
5.96%
Current Industry
17.1%
ABBV's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ABBV vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ABBV$14.30B$4.20B-16.08%$2.36
JNJ$34.70B$21.81B+6.83%$9.06
NVS$27.72B$13.65B+16.64%$6.91
AZN$17.68B$7.77B+34.22%$2.51
MRK$26.05B$17.43B+11.60%$6.89
View Top General Drug Manufacturer Stocks

ABBV earnings dates

Next earnings date
Jul 23, 2025

Abbvie Earnings Reports & History FAQ

What were Abbvie's earnings last quarter?

On ABBV's earnings call on Invalid Date, Abbvie (NYSE: ABBV) reported Q1 2025 earnings per share (EPS) of $0.72, up 6.49% year over year. Total ABBV earnings for the quarter were $1.29 billion. In the same quarter last year, Abbvie's earnings per share (EPS) was $0.77.

If you're new to stock investing, here's how to buy Abbvie stock.

When does Abbvie report earnings?

The next ABBV earnings call is Invalid Date. Add ABBV to your watchlist to be reminded of Abbvie's next earnings date.

Is Abbvie profitable or losing money?

As of the last Abbvie earnings report, Abbvie is currently profitable. Abbvie's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $4.20 billion, a 30% decrease year over year.

What was ABBV's earnings growth in the past year?

As of Abbvie's earnings date in Invalid Date, Abbvie's earnings has grown -29.97% year over year. This is 144.13 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 114.16%. ABBV earnings in the past year totalled $4.20 billion.

What are Abbvie's earnings expectations?

The current EPS estimate for Abbvie's earnings report in Invalid Date is $3.22.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.